The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter cooperative group study of late effects after high-risk neuroblastoma: COG ALTE15N2—LEAHRN study.
 
Tara O. Henderson
Other Relationship - Seagen
(OPTIONAL) Uncompensated Relationships - National Academies of Medicine, Engineering and Sciences Committee on Disability and Childhood Cancer
 
Jenna K. Bardwell
No Relationships to Disclose
 
Pei-Chi Kao
No Relationships to Disclose
 
Paul C. Nathan
No Relationships to Disclose
 
Wendy Landier
Research Funding - Merck Sharp & Dohme (Inst)
 
Sogol Mostoufi-Moab
No Relationships to Disclose
 
Tara M. Brinkman
No Relationships to Disclose
 
Julie R. Park
No Relationships to Disclose
 
Saro Armenian
No Relationships to Disclose
 
Arlene Naranjo
Consulting or Advisory Role - Novartis
 
Meera Subramaniam
No Relationships to Disclose
 
Araz Marachelian
No Relationships to Disclose
 
Sharon Diskin
No Relationships to Disclose
 
Wendy B. London
Consulting or Advisory Role - Healthcasts; Jubilant Radiopharma; Merck; Y-mAbs Therapeutics
Research Funding - Agios; Aileron Therapeutics; Bluebird Bio; Bristol-Myers Squibb; Novartis
 
Lisa Diller
Stock and Other Ownership Interests - Alcon (I); Amgen (I); Baxter (I); crispr therapeutics (I); LabCorp (I); Novartis (I); Novo Nordisk (I); Roche (I); Sangamo Therapeutics (I); Sanofi/Aventis (I)
Patents, Royalties, Other Intellectual Property - My husband holds a patent with Massachusetts General Hospital for a drug currently in clinical trials. The drug is an inhibitor of BMP-1 (Alk2) receptor and is being studied in anemia of myelodysplastic syndrome and high-hepcidin level-associated anemias. (I)